Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 2/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978010 | 0.90 | NR4A2 (0.60) | POLBNR4A2MRGPRX4MAOBCASP6 | |
| SCHEMBL23978042 | 0.88 | MAOB (0.60) | POLBNR4A2MAOBBCL2CASP6 | |
| SCHEMBL1138750 | 0.81 | MAOB (0.53) | POLBNR4A2MAOBKMT2AMAPT | |
| SCHEMBL23978033 | 0.80 | MRGPRX4 (0.69) | POLBNR4A2MRGPRX4MAOBKMT2A | |
| SCHEMBL4299408 | 0.78 | CASP6 (0.58) | POLBCASP6KMT2AMAPTMEN1 | |
| SCHEMBL29897189 | 0.78 | CASP6 (0.58) | POLBCASP6KMT2AMAPTMEN1 | |
| SCHEMBL23978245 | 0.77 | MAOB (0.60) | NR4A2MAOBBCL2CASP6MAPT | |
| SCHEMBL4253888 | 0.77 | POLB (1.00) | POLBCASP6KMT2AATMMAPT | |
| SCHEMBL23978217 | 0.77 | MRGPRX4 (0.60) | POLBNR4A2MRGPRX4MAOBKMT2A | |
| SCHEMBL28376698 | 0.76 | MAOB (0.66) | MAOBKMT2AATMMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | POLB 1240/4885NR4A2 3359/4885MRGPRX4 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.